Total Payments
$23,402
2024 Payments
$8,859
Companies
14
Transactions
35
Medicare Patients
559
Medicare Billing
$112,448
Payment Breakdown by Category
Consulting$14,936 (63.8%)
Other$3,600 (15.4%)
Travel$2,885 (12.3%)
Food & Beverage$1,981 (8.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,936 | 7 | 63.8% |
| Honoraria | $3,600 | 2 | 15.4% |
| Travel and Lodging | $2,885 | 6 | 12.3% |
| Food and Beverage | $1,981 | 20 | 8.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,902 | 7 | $0 (2024) |
| BeiGene USA, Inc. | $4,017 | 4 | $0 (2024) |
| ARRAY BIOPHARMA INC | $3,600 | 2 | $0 (2021) |
| Merrimack Pharmaceuticals, Inc. | $2,396 | 3 | $0 (2017) |
| TAIHO ONCOLOGY, INC. | $2,200 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $2,145 | 5 | $0 (2021) |
| Seagen Inc. | $1,375 | 1 | $0 (2022) |
| Ipsen Bioscience Inc | $1,318 | 2 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $956.00 | 3 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $159.73 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,859 | 12 | E.R. Squibb & Sons, L.L.C. ($4,766) |
| 2023 | $2,200 | 1 | TAIHO ONCOLOGY, INC. ($2,200) |
| 2022 | $1,375 | 1 | Seagen Inc. ($1,375) |
| 2021 | $5,350 | 3 | ARRAY BIOPHARMA INC ($3,600) |
| 2020 | $956.00 | 3 | Bayer HealthCare Pharmaceuticals Inc. ($956.00) |
| 2019 | $351.17 | 3 | Celgene Corporation ($126.57) |
| 2018 | $1,381 | 4 | Ipsen Bioscience Inc ($1,318) |
| 2017 | $2,930 | 8 | Merrimack Pharmaceuticals, Inc. ($2,396) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug), JEMPERLI, ZEJULA | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,880.00 | General |
| 06/10/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| Category: Oncology | ||||||
| 06/10/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Travel and Lodging | In-kind items and services | $750.00 | General |
| Category: Oncology | ||||||
| 06/10/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Travel and Lodging | In-kind items and services | $534.50 | General |
| Category: Oncology | ||||||
| 06/10/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $107.33 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 05/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $325.13 | General |
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $383.29 | General |
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $134.15 | General |
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.96 | General |
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.53 | General |
| 03/24/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 11/03/2022 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 12/03/2021 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $2,700.00 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2021 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $900.00 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 01/22/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $856.00 | General |
| Category: Oncology | ||||||
| 01/22/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 01/22/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 06/13/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $126.57 | General |
| Category: Oncology | ||||||
| 06/03/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $109.92 | General |
| Category: Oncology/Endocrinology | ||||||
| 06/02/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $114.68 | General |
| 10/23/2018 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $12.86 | General |
| Category: Interventional Oncology | ||||||
| 03/10/2018 | Ipsen Bioscience Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $756.42 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 171 | 375 | $317,109 | $30,085 |
| 2022 | 3 | 117 | 264 | $181,707 | $21,262 |
| 2021 | 3 | 128 | 385 | $152,638 | $30,270 |
| 2020 | 6 | 143 | 329 | $134,005 | $30,831 |
Total Patients
559
Total Services
1,353
Medicare Billing
$112,448
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 60 | 239 | $200,301 | $18,560 | 9.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 29 | 29 | $41,447 | $4,183 | 10.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 35 | 50 | $29,802 | $2,489 | 8.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 20 | $17,072 | $2,224 | 13.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 18 | $21,292 | $2,113 | 9.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 12 | 19 | $7,195 | $516.12 | 7.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 49 | 180 | $121,720 | $14,183 | 11.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $35,010 | $4,158 | 11.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 42 | 58 | $24,977 | $2,922 | 11.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 57 | 265 | $109,180 | $21,685 | 19.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 53 | 102 | $28,968 | $5,709 | 19.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $14,490 | $2,876 | 19.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 47 | 171 | $70,452 | $16,655 | 23.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 92 | $26,128 | $5,875 | 22.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 20 | $11,120 | $2,616 | 23.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 13 | 13 | $10,465 | $2,069 | 19.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 22 | $8,778 | $2,011 | 22.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $7,062 | $1,605 | 22.7% |
About Dr. Patrick Boland, MD
Dr. Patrick Boland, MD is a Hematology & Oncology healthcare provider based in New Brunswick, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2008. The National Provider Identifier (NPI) number assigned to this provider is 1982870333.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Boland, MD has received a total of $23,402 in payments from pharmaceutical and medical device companies, with $8,859 received in 2024. These payments were reported across 35 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($14,936).
As a Medicare-enrolled provider, Boland has provided services to 559 Medicare beneficiaries, totaling 1,353 services with total Medicare billing of $112,448. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location New Brunswick, NJ
- Active Since 05/06/2008
- Last Updated 11/12/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982870333
Products in Payments
- TEVIMBRA (Drug) $4,017
- BRAFTOVI (Drug) $3,600
- ONIVYDE (Drug) $2,396
- LONSURF (Drug) $2,200
- TUKYSA (Drug) $1,375
- Onivyde (Drug) $1,318
- Stivarga (Drug) $956.00
- KEYTRUDA (Biological) $155.50
- SIR-Spheres Microspheres (Device) $130.91
- Abraxane (Drug) $126.57
- SOMATULINE DEPOT (Drug) $109.92
- Somatuline Depot (Drug) $49.81
- OJJAARA (Drug) $29.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New Brunswick
Dr. Rajneesh Nath, Md, MD
Hematology & Oncology — Payments: $36,340
Hematology & Oncology $36,340
Dr. Rajat Bannerji, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $21,204
Hematology & Oncology $21,204
Anna Ferrari, M.d, M.D
Hematology & Oncology — Payments: $4,962
Hematology & Oncology $4,962
Dr. Ogechukwu Egini, M.d, Ms, M.D, MS
Hematology & Oncology — Payments: $3,282
Hematology & Oncology $3,282
Aaron Ciner, M.d, M.D
Hematology & Oncology — Payments: $98.50
Hematology & Oncology $98.50
Beatriz Lega, Md, MD
Hematology & Oncology
Hematology & Oncology